GLP‐1 receptor agonists in patients with MGUS: A real‐world propensity‐matched study

📖 Top 20% JournalOct 22, 2025European journal of clinical investigation

Effects of GLP-1 receptor drugs in patients with MGUS: a matched real-world study

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Among 30,034 matched patients, 823 in the GLP-1 RA group progressed to symptomatic multiple myeloma or died compared to 2317 in the control group.

GLP-1 RA use is associated with significantly improved progression-free survival (PFS) and overall survival (OS).
The hazard ratios for PFS and OS are 0.63 (95% CI: 0.58–0.68) and 0.61 (95% CI: 0.56–0.66), respectively.
A reduced risk of progression to symptomatic multiple myeloma is noted, with a hazard ratio of 0.82 (95% CI: 0.69–0.98).
GLP-1 RA users had a lower cumulative incidence of major cardiovascular events, such as myocardial infarction and heart failure.
Differences in cardiovascular events were not confirmed in time-to-event analyses.

AI simplified

BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell disorder with potential progression to multiple myeloma (MM). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated potential anti-neoplastic properties. This study evaluated the association between GLP-1 RA use and clinical outcomes in individuals with MGUS and concurrent DM, overweight or obesity.

METHODS: A retrospective cohort study was conducted using the TriNetX global health research network. Adults with MGUS and either DM or overweight/obesity were identified. Propensity score matching (1:1) was performed, resulting in two balanced cohorts. The primary outcome was progression-free survival (PFS). Secondary outcomes included overall survival (OS), time to progression to multiple myeloma (MM) and major cardiovascular events, including myocardial infarction (MI), ischemic stroke, ischemic heart disease and heart failure (HF).

RESULTS: Among 30,034 matched patients, 823 patients in the GLP-1 RA group and 2317 in the control group progressed to symptomatic MM or died. GLP-1 RA use was associated with significantly improved PFS [HR (95% CI): .63 (.58-.68)] and OS [HR (95% CI): .61 (.56-.66)]. A reduced risk of progression to symptomatic MM was also observed [HR (95% CI): .82 (.69-.98)]. GLP-1 RA users had lower cumulative incidence of MI, HF, ischemic heart disease, and stroke; however, these differences were not confirmed in time-to-event analyses.

CONCLUSIONS: GLP-1 RA therapy was associated with significantly improved PFS and OS in MGUS patients with metabolic comorbidities. While fewer cardiovascular events were observed, these findings were not statistically confirmed over time.

Full Text

Full text is available at the source.

View full text ↗